{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Neuropathies&page=3", "query": { "condition": "Inherited Neuropathies", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 270, "total_pages": 27, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Neuropathies&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inherited+Neuropathies&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-17T13:58:27.299Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03023540", "title": "Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Charcot-Marie-Tooth Disease, Type IA" ], "interventions": [ { "name": "PXT3003", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pharnext S.C.A.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": "67 Years", "sex": "ALL", "summary": "17 Years to 67 Years" }, "enrollment_count": 187, "start_date": "2017-03-07", "completion_date": "2024-12-31", "has_results": false, "last_update_posted_date": "2024-02-20", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 9, "location_summary": "Los Angeles, California • Gainesville, Florida • Kansas City, Kansas + 6 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Kansas City", "state": "Kansas" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03023540" }, { "nct_id": "NCT03295071", "title": "REALITY LHON Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Leber Hereditary Optic Neuropathy" ], "interventions": [ { "name": "Patient-reported outcomes (PROs)", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "GenSight Biologics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 44, "start_date": "2018-01-03", "completion_date": "2020-07-01", "has_results": false, "last_update_posted_date": "2026-03-02", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 5, "location_summary": "Pasadena, California • Atlanta, Georgia • Boston, Massachusetts + 2 more", "locations": [ { "city": "Pasadena", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03295071" }, { "nct_id": "NCT02435940", "title": "Inherited Retinal Degenerative Disease Registry", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Eye Diseases Hereditary", "Retinal Disease", "Achromatopsia", "Bardet-Biedl Syndrome", "Bassen-Kornzweig Syndrome", "Batten Disease", "Best Disease", "Choroidal Dystrophy", "Choroideremia", "Cone Dystrophy", "Cone-Rod Dystrophy", "Congenital Stationary Night Blindness", "Enhanced S-Cone Syndrome", "Fundus Albipunctatus", "Goldmann-Favre Syndrome", "Gyrate Atrophy", "Juvenile Macular Degeneration", "Kearns-Sayre Syndrome", "Leber Congenital Amaurosis", "Refsum Syndrome", "Retinitis Pigmentosa", "Retinitis Punctata Albescens", "Retinoschisis", "Rod-Cone Dystrophy", "Rod Dystrophy", "Rod Monochromacy", "Stargardt Disease", "Usher Syndrome" ], "interventions": [], "intervention_types": [], "sponsor": "Foundation Fighting Blindness", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 20000, "start_date": "2014-06", "completion_date": "2037-06", "has_results": false, "last_update_posted_date": "2026-05-19", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 1, "location_summary": "Columbia, Maryland", "locations": [ { "city": "Columbia", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02435940" }, { "nct_id": "NCT07175038", "title": "A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pulmonary Arterial Hypertension (PAH)", "Pulmonary Hypertension, Interstitial Lung Disease" ], "interventions": [ { "name": "ROC-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AllRock Bio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 40, "start_date": "2025-10-01", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 11, "location_summary": "Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 8 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Rancho Cordova", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07175038" }, { "nct_id": "NCT06465810", "title": "Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Transthyretin Amyloidosis", "ATTR-CM", "ATTRv-PN", "ATTR", "ATTR-Mixed", "hATTR" ], "interventions": [ { "name": "Treatment of transthyretin (ATTR) amyloidosis in observational study setting", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "ALL", "summary": "18 Years to 130 Years" }, "enrollment_count": 1850, "start_date": "2024-06-25", "completion_date": "2031-12-31", "has_results": false, "last_update_posted_date": "2026-09-23", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 33, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 24 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06465810" }, { "nct_id": "NCT00876187", "title": "A Study of Tanezumab in Adults With Chronic Low Back Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Low Back Pain" ], "interventions": [ { "name": "Tanezumab 20 mg IV", "type": "BIOLOGICAL" }, { "name": "Placebo for naproxen", "type": "DRUG" }, { "name": "Tanezumab 10 mg IV", "type": "BIOLOGICAL" }, { "name": "Tanezumab 5 mg IV", "type": "BIOLOGICAL" }, { "name": "Placebo for tanezumab", "type": "BIOLOGICAL" }, { "name": "Naproxen", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1359, "start_date": "2009-06-15", "completion_date": "2011-02-01", "has_results": true, "last_update_posted_date": "2021-07-07", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 135, "location_summary": "Anniston, Alabama • Birmingham, Alabama • Hueytown, Alabama + 101 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Anniston", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Hueytown", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT00876187" }, { "nct_id": "NCT03094832", "title": "Study of Miransertib (MK-7075) in Participants With PIK3CA-related Overgrowth Spectrum and Proteus Syndrome (MOSAIC) (MK-7075-002)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "PIK3CA-Related Overgrowth Spectrum (PROS)/Proteus Syndrome" ], "interventions": [ { "name": "Miransertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": null, "sex": "ALL", "summary": "2 Years and older" }, "enrollment_count": 50, "start_date": "2017-05-16", "completion_date": "2022-04-11", "has_results": true, "last_update_posted_date": "2023-04-13", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 6, "location_summary": "Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 3 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03094832" }, { "nct_id": "NCT05557162", "title": "Artificial Intelligence Enhanced ECG to Detect Cardiac Amyloidosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cardiac Amyloidosis" ], "interventions": [ { "name": "AI ECG Amyloid algorithm", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20143, "start_date": "2023-06-19", "completion_date": "2025-07-23", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Eau Claire", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557162" }, { "nct_id": "NCT07223632", "title": "Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Charcot Marie Tooth Disease (CMT)", "Neuromuscular Diseases (NMD)" ], "interventions": [ { "name": "VCA-894A", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vanda Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "FEMALE", "summary": "Female only" }, "enrollment_count": 1, "start_date": "2025-05-13", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT07223632" }, { "nct_id": "NCT01960023", "title": "Safety and Efficacy Study of Neratinib and Cetuximab to Treat Patients With Quadruple Wild-Type Metastatic Colorectal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "NSABP Foundation Inc", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2013-10", "completion_date": "2016-07-13", "has_results": false, "last_update_posted_date": "2021-10-27", "last_synced_at": "2026-10-17T13:58:27.299Z", "location_count": 12, "location_summary": "Gainesville, Florida • Orlando, Florida • Boise, Idaho + 7 more", "locations": [ { "city": "Gainesville", "state": "Florida" }, { "city": "Orlando", "state": "Florida" }, { "city": "Boise", "state": "Idaho" }, { "city": "Decatur", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01960023" } ] }